摘要
Dear Editor,Approximately 25%of acute myeloid leukemia(AML)carries FLT3-ITD(internal tandem duplication)oncogenic mutations.Although FLT3 kinase inhibitors have already been successfully used in the clinic for treating FLT3-ITD-positive AML,acquired drug resistance is observed after the prolonged treatment.Therefore,seeking a new therapeutic strategy is still imperative for FLT3-ITD-positive AML.
基金
supported by the National Natural Science Foundation of China(Grant Nos.81903650,81803366,81673469,81773777)
the Natural Science Foundation of Anhui Province(Grant Nos.2008085MH274,1808085MH268)
the China Postdoctoral Science Foundation(Grant No.2019M652057)
the Postdoctoral Science Foundation of Anhui Province(Grant No.2019B300)
the Frontier Science Key Research Program of CAS(Grant No.QYZDB-SSW-SLH037)
the Collaborative Innovation Program of Hefei Science Center,CAS(Grant No.2019HSC-CIP011)
the CASHIPS Director’s Fund(Grant Nos.BJPY2019A03,YZJJZX202011).
